Exploring a Recently Approved Therapy for Demodex

EP: 1.Overview of Demodex Blepharitis

EP: 2.Pathophysiology of Demodex Blepharitis

EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice

EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis

EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis

EP: 6.Treatment of Demodex Blepharitis

EP: 7.Diagnosis and Prevalence of Demodex Blepharitis

Now Viewing

EP: 8.Exploring a Recently Approved Therapy for Demodex

EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis

EP: 10.Outlook on the Future of Demodex Blepharitis Treatment

EP: 11.Understanding Demodex Blepharitis Pathogenesis

EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment

EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment

This is a video synopsis/summary of an Insights involving Neda Shamie, MD.

There is a recently FDA-approved treatment for Demodex blepharitis called Xdemvy (lotilaner ophthalmic solution 0.25%). Xdemvy targets and paralyzes an enzyme only found in the Demodexmite, effectively eradicating the mite. It is used twice daily for 6 weeks to cover the full life cycle. Over the treatment course, thedrug shows an impressively effective response in not just controlling but eradicating Demodexinfestation. It is a fast, highly effective, and reliable treatment.

In studies and clinical practice, Xdemvy eyedrops have not had significant adverse effects. Most patients find it soothing to the ocular surface with no adverse reactions. About 10% of study patients described a burning sensation upon drop installation. Less than 2% developed chalazion or hordeolum while on treatment. Overallit is very safe, highly effective and welltolerated, with a 6-week, twice-daily course, which supports good compliance. Many patients report completing the full course, motivated to control their disease.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.